Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03393000 |
|
Recruitment Status :
Completed
First Posted : January 8, 2018
Last Update Posted : January 11, 2021
|
Sponsor:
Diffusion Pharmaceuticals Inc
Information provided by (Responsible Party):
Diffusion Pharmaceuticals Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | November 6, 2020 |
| Actual Study Completion Date : | November 6, 2020 |